Anavex Life Sciences Corp (AVXL)

[Anshu2]

I think the biggest problem with P2b/P3 is not the filed ADL endpoint. The biggest problem is the lack of dosage-arm data, which is highly likely to have a terrible p-value if any at all. FDA can't possibly approve a drug without a dosage recommendation -- and a dosage recommendation can only come from dosage-level data.